JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer

Abstract

BackgroundHuman microsatellite-stable (MSS) colorectal cancers (CRCs) are immunologically “cold” tumour subtypes characterized by reduced immune cytotoxicity. The molecular linkages between immune-resistance and human MSS CRC is not clear.MethodsWe used transcriptome profiling, in silico analysis, immunohistochemistry, western blot, RT-qPCR and immunofluorescence staining to characterize novel CRC immune biomarkers. The effects of selective antagonists were tested by in vitro assays of long term viability and analysis of kinase active forms using anti-phospho antibodies.ResultsWe identified the lymphocyte antigen 6 complex, locus G6D (LY6G6D) as significantly overexpressed (around 15-fold) in CRC when compared with its relatively low expression in other human solid tumours. LY6G6D up-regulation was predominant in MSS CRCs characterized by an enrichment of immune suppressive regulatory T-cells and a limited repertoire of PD-1/PD-L1 immune checkpoint receptors. Coexpression of LY6G6D and CD15 increases the risk of metastatic relapse in response to therapy. Both JAK-STAT5 and RAS-MEK-ERK cascades act in concert as key regulators of LY6G6D and Fucosyltransferase 4 (FUT4), which direct CD15-mediated immune-resistance. Momelotinib, an inhibitor of JAK1/JAK2, consistently abrogated the STAT5/LY6G6D axis in vitro, sensitizing MSS cancer cells with an intact JAK-STAT signaling, to efficiently respond to trametinib, a MEK inhibitor used in clinical setting. Notably, colon cancer cells can evade JAK2/JAK1-targeted therapy by a reversible shift of the RAS-MEK-ERK pathway activity, which explains the treatment failure of JAK1/2 inhibitors in refractory CRC.ConclusionsCombined targeting of STAT5 and MAPK pathways has superior therapeutic effects on immune resistance. In addition, the new identified LY6G6D antigen is a promising molecular target for human MSS CRC.Electronic supplementary materialThe online version of this article (10.1186/s13046-018-1019-5) contains supplementary material, which is available to authorized users.

JAK3 and TYK2 Serve as Prognostic Biomarkers and Are Associated with Immune Infiltration in Stomach Adenocarcinoma

“…An increasing number of studies have suggested an interaction between immune response and pathophysiological processes [ 21 , 22 ]. Moreover, JAKs play a critical role in immune regulation by invoking intracellular signaling pathways in cancers [ 23 ]. Therefore, we next evaluated the correlation between JAK3/TYK2 and immune infiltration in STAD.…”

Immune Resistance and EGFR Antagonists in Colorectal Cancer

“…CRCs require interaction with many different host immune cell populations for their growth and survival, including regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC), mast cells, and tumor associated macrophages (TAM) [55]. Recent studies suggest that a substantial portion of the effects attributed to EGFR antagonist treatment may be based on indirect effects beyond cancer cells [40,41,42,55,56,57,58,59,60,61,62].…”

An Autophagy-Related Gene Signature Predicts Prognosis of Early Stage Colorectal Cancer

“…GSEA revealed that the ATG signature included genes that were robustly involved in multiple immune/ in ammatory pathways including IL6/JAK/STAT3, IL2/STAT5, IFN-α, IFN-γ, TNF-α/NF-κB, and the in ammatory response presented a particular relation to CRC proliferation or prognosis as previous studies revealed [21][22][23][24][25]. As our ndings suggested that a high autophagy risk score correlated with the downregulation of these immune/ in ammatory pathways, we speculated that autophagy might play a role in CRC tumorigenesis and tumor proliferation via an anti-immune/ anti-in ammatory response.…”